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Abstract 
It is well documented that the Ca 2+ channel antagonist verapamil can reverse multidrug resistance in cancer cells by decreasing 
P-glycoprotein mediated rug efflux. However, less information is available about effects of verapamil on drug-phospholipid interactions 
and on passive diffusion of drugs across the membrane, which both may play an important role in resensitizing cells to anti-cancer d ugs. 
Therefore we studied the binding of verapamil to model membranes (large unilamellar vesicles) composed of various phospholipids and 
biological membranes. An increase of the amount of anionic phospholipids resulted in an enhanced binding of verapamil. Competition 
between verapamil and the anti-cancer drug and P-glycoprotein substrate doxorubicin for binding to anionic phospholipids was observed 
in model membranes composed of synthetic lipids, or composed of native Escherichia coli phospholipid mixtures, and in cytoplasmic 
membrane vesicles of this organism. Furthermore, verapamil specifically increased the rate of passive diffusion of doxorubicin across 
model membranes containing anionic phospholipids. It can be concluded that besides the decrease of P-glycoprotein mediated effiux at 
least two other effects may account for an increase of the internal (free and DNA-bound) doxorubicin concentration i  the presence of 
verapamil; (i) a decrease of binding to anionic phospholipids in plasma-and intracellular membranes and (ii) an increase of the rate of 
passive import of doxorubicin across the plasma membrane. 
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1. Introduction 
Doxorubicin is a potent and widely applied anti-cancer 
drug, that interacts with DNA, DNA-associated proteins 
[1,2] and membranes. In membranes, anionic phospho- 
lipids are important argets [3-7], and membrane binding 
involves electrostatic interactions as well as penetration of 
the electrostatically-bound drug between the acyl chains 
Abbreviations: CF, 6-carboxyfluorescein; CL, cardiolipin; DOPC, 
1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPE, 1,2-dioleoyl-sn- 
glycero-3-phosphoethanolamine; DOPS 1,2-dioleoyl-sn-glycero-3-phos- 
phoserine; EGTA, ethyleneglycol bis(/3-aminoethyl ether)-N,N,N',N'-te- 
traacetic acid; LUVET, large unilamellar vesicles prepared by extrusion; 
mdr, multidrug resistance; Pipes, 1,4-piperazinediethanesulfonic acid; 
SUV, small unilamellar vesicles (prepared by sonication). 
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[6,7]. The uncharged form of the drug is transported via 
passive diffusion across the membrane [8], which is thought 
to be the main route of entry into a cell. The driving force 
for this process is the concentration gradient, maintained 
by a pH gradient (inside acid) and initially also by accu- 
mulation in acidic organelles and DNA-binding [1-3,8-  
11 ]. Effiux of doxorubicin can occur via passive diffusion 
or by an active drug pump (for a review see [12]). Ac- 
quired resistance of cancer cells against drugs is frequently 
accompanied by the appearance of a 170 kDa plasma 
membrane protein, the P-glycoprotein (Pg-170), which 
utilizes ATP to actively extrude a variety of structurally 
non-related rugs, including anthracyclines such as dox- 
orubicin [12]. Usually, these drugs are moderately hy- 
drophobic. They have a planar geometry, and are often 
positively charged on a (protonable) nitrogen atom [12]. 
Multidrug resistance (mdr) is an undesirable phenomenon 
in anti-cancer treatment and many strategies developed to 
overcome this resistance include the use of so-called 
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Fig. 1. Structures of (A) doxorubicin and (B) verapamil. 
chemo-sensitizers or multidrug resistance reversal agents 
[12-14]. 
Verapamil is one of the best studied chemo-sensitizers 
[13,15]. It is a Ca 2+ channel antagonist, which has in 
common with P-glycoprotein substrates that it is moder- 
ately hydrophobic and positively charged at physiological 
pH [14]. In Fig. 1 the structures of verapamil and doxoru- 
bicin are shown. It is assumed that verapamil reverses 
multidrug resistance by inhibiting P-glycoprotein mediated 
drug effiux. This occurs, depending on the drug investi- 
gated, by a direct competition for drug effiux or by binding 
at the enzyme at a different binding site [16-20]. In 
contrast o anti-cancer drugs such as doxorubicin, vera- 
pamil does not bind to DNA and is not (or much less) 
toxic to cells [14]. Upon addition of verapamil resistant 
cell lines reverse with respect o morphology [21], drug 
transport rates [22-24], steady-state intracellular drug con- 
centrations [25], and intracellular distribution of drugs 
[26-29] and become comparable to the sensitive parental 
strains. 
Studies on the mechanism of mdr reversal by verapamil 
have focused on the effect on active effiux. However, very 
little information is available about the binding of vera- 
pamil to membranes, its effect on the intrinsic properties of 
membranes, and the potential consequences of verapamil- 
phospholipid interactions for sensitivity to anti-cancer d ugs 
[30]. Therefore, we first investigated the binding behavior 
of verapamil towards model- and biological membranes, 
paying special attention to negatively charged phospho- 
lipids. Subsequently, competition between doxorubicin and 
verapamil for binding was studied, using Escherichia coli 
inner membrane vesicles as a model for biological mem- 
branes. In previous tudies this organism was used to study 
the influence of the lipid composition on drug interaction 
in biological membranes, ince in contrast o mammalian 
cancer cells the phospholipid composition of this organism 
can easily be manipulated [7]. Finally, the effect of vera- 
pamil on the rate of passive transport of doxorubicin was 
studied. The implications of our findings for the effects of 
verapamil on intracellular doxorubicin concentrations and 
on drug pumping by the P-glycoprotein are discussed. 
2. Materials and methods 
2.1. Growth of Escherichia coli and preparation of inner 
membrane vesicles 
Escherichia coli strain MRE600 was grown in Luria 
broth (10 g 1 i bacto-tryptone (Sigma), 5 g 1-1 yeast 
extract (Sigma), and 10 g 1-~ NaC1). Cells were grown at 
37°C until late logarithmic phase (A660 0.6-0.8) ,  chilled 
on ice, and harvested by low-speed centrifugation at 4°C. 
Spheroplasts and fight-side out inner membrane vesicles 
were prepared and isolated as described [31]. Inside-out 
inner membrane vesicles were prepared with modifications 
as described [32,33]. Inside-out and fight-side out inner 
membrane vesicles were washed in Pipes buffer (10 mM 
Pipes, 100 mM NaC1, 1 mM EGTA, pH 7.4), frozen in 
liquid nitrogen and stored at -80°C. The total Pi content 
was determined according to [34]. Under these circum- 
stances the amount of DNA-P~ is 2-6% in inside-out and 
6-9% in right-sideout inner membrane vesicles and the 
amount of 2-keto-3-deoxyoctonate 0.01-0.03 mol/mol to- 
tal Pi [7]. 
2.2. Isolation and determination of the composition of 
Escherichia coli lipids 
Total lipid extracts were prepared from washed E. coli 
cells [35] by extracting the lipids [36] and removing pro- 
teins and neutral lipids on a silica column. Lipids were 
separated by two dimensional high-performance thin-layer 
chromatography (Kieselgel 60, Merck, Germany) with 
chloroform/methanol/ammonia/water (68:28:2:2, v /v)  
in the first dimension and chloroform/methanol/acetic 
acid (65:25:10, v /v)  in the second dimension. Spots were 
visualized with 12 and excised for P~ quantification. 
2.3. Preparation of small unilamellar vesicles (SUV) and 
large unilamellar vesicles (LUVET) with or without en- 
closed DNA 
SUV composed of DOPC or DOPG were prepared in 
Pipes buffer by sonication as described [6]. LUVET used 
in the binding experiments and carboxyfluorescein ffiux 
measurements were prepared in Pipes buffer by extrusion 
through polycarbonate filters with 400 nm pores (Costar- 
Nucleopore Europe, Badhoevedorp, the Netherlands) as 
described previously [7]. LUVET with (or as a control 
without) DNA enclosed used for transport experiments 
were prepared by the method described by Speelmans et 
al. [371. 
G. Speelmans et al. / Biochimica et Biophysica Acta 1238 (1995) 137-146 139 
2.4. Binding assays 
Doxorubicin binding to Q 400 nm LUVET and E. coli 
inner membrane vesicles was assayed according to de 
Wolf et al. [7], by mixing 100 /xl of membrane suspen- 
sions (10 mM Pi, which is about 7.5-8 g lipid per 1) with 
900 /xl of doxorubicin solution in the range of 25 to 250 
/xM (final concentration) (both in Pipes buffer), incubating 
duplicate samples for 1 h in the dark and at room tempera- 
ture, and pelleting the vesicles and bound drug (60 min at 
436000 × g and 20°C, Beckman TLA 100.2 rotor). The 
top 800 /zl was collected for determination of free drug. 
The amount of lipid-P i in the supernatant was negligible 
(less than 0.5% of the total Pi)- Blanks without lipids were 
used to determine the amount of total drug. Corrections 
were made for binding of doxorubicin to tubes (which was 
0.30 
0.25 
O.. 
-6 
E 0.20 
"5 
E 
'~  0 .15  
0.10 "o  
O 
110 
0.05 
0.00 
A / 
I , I , I , 
50 100 150 200 
Free veraparnil (/JM) 
r, 
-6 
E 
-6 
E 
O) 
'IO 
rn  
1.00 
0.75 
0.50 
0.25 
0.00 
0 
B 
O.lC , . . 
0,0~ 
!. 
25 50 75 1 oo 
PG incorporated (%) 
0.10 
0.08 
e~ 
o 
E 
"5 0.06 
E 
E 
~ o.04 I l J  
m 0.02 
0.00 
0 50 1 O0 I 50 200 
Free verapamil (/.JM) 
Fig. 2. Binding of verapamil to membranes. (A) Binding of verapamil to LUVET composed of DOPC containing 0% ([]), 5% (• ) ,  25% (O), or 100% 
(©) of the anionic pbospholipid DOPG. (B) Binding of verapamil (0 )  or doxorubicin (©) to DOPC LUVET with an increasing amount of incorporated 
DOPG. Drug binding was compared at a free drug concentration of 50 txM. The doxorubicin binding data were obtained from [7]. The inset shows an 
enlargement a low % DOPG graph (C) Binding of verapamil to LUVET composed of DOPC/DOPG (3:1) (0) ,  DOPE/DOPG (3:1) (O), LUVET 
composed of E. coli lipids (11), and to inside-out inner membrane vesicles of E. coli (D). 
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low). The concentration of doxorubicin was determined 
after dilution to 5-10/xM drug, by light absorption at 480 
nm using an extinction coefficient of 1.06. l 0  4 M -1 
cm-  !. 
Verapamil binding experiments were performed as de- 
scribed above for the doxorubicin binding assay. Vera- 
pamil was solubilized in 96% ethanol to a concentration f
about 15 mM and subsequently diluted in water to 5 mM 
final concentration and used within 4 h. Verapamil was 
added to the LUVET (approximately 1 mM lipid-P~) to 
final concentrations of 50 to 250 /zM. To the control 
LUVET the same volume of ethanol/water, 1:2 (v/v)  was 
added. The concentration of verapamil was determined by 
light absorption at 279 nm using an extinction coefficient 
of 6.09. 10 3 M -1 cm-i  [38]. 
Verapamil and doxorubicin binding competition experi- 
ments were performed as follows: After incubation of 
vesicles with doxorubicin for 1 h at room temperature in 
the dark verapamil was added, and incubation was pro- 
longed for 1 h. Upon reversing the sequence of addition no 
differences were observed. The presence of verapamil did 
not influence the molar extinction coefficient of doxoru- 
bicin. Verapamil measurements in the presence of doxoru- 
bicin, on the other hand, had to be corrected for the 
presence of doxorubicin (A279.do x = 0.70 A480,do x). 
2.5. Transport experiments 
Transport of doxorubicin across model membranes in 
which DNA was enclosed, was determined from the rate of 
fluorescence decrease (Exc. 490 nm, Em. 594 nm) in an 
Amino fluorimeter as described [37]. The fraction of free 
doxorubicin was determined in separate quilibrium dialy- 
sis experiments and corrections were made for changes in 
quantum yield and the fraction of free doxorubicin by 
binding to membranes upon addition of DNA-containing 
LUVET [37]. The permeability coefficient was calculated 
according to [37] and an area of 31.5 ~2 per lipid-P i for 
two opposing phospholipid molecules (in a bilayer) was 
assumed [37]. 
2.6. Other methods 
Carboxyfluorescein ffiux experiments were performed 
as described previously [6]. 
2.7. Materials 
Doxorubicin (Pharmachemie, the Netherlands) was 
shown to be pure by high-performance thin-layer liquid 
chromatography [3] and dissolved just before use. DNA 
(Type I from calf thymus), DNAse I (type DN-25 from 
bovine pancreas) and verapamil-hydrochloride were ob- 
tained from Sigma, USA. Phospholipids were obtained 
from Avanti Polar-Lipids, USA, and checked for purity by 
thin-layer chromatography. 6-Carboxyfluorescein was ob- 
tained from Kodak, USA, and purified according to [39]. 
3. Results 
3.1. Binding of verapamil to model membranes containing 
various amounts of anionic phospholipids and biological 
membranes 
From previous studies it is known that binding of 
doxorubicin to membranes i largely determined by elec- 
trostatic interactions, and that binding increases with the 
amount of anionic phospholipids [7]. Therefore, we studied 
binding of verapamil to LUVET composed of the zwitteri- 
onic phospholipid DOPC containing a variable amount of 
the negatively charged phospholipid DOPG. An enhanced 
binding of verapamil to the membranes was observed upon 
increasing the amount of incorporated DOPG, indicating 
the involvement of electrostatic interactions (Fig. 2A). 
Under the experimental conditions of Fig. 2A 72% of the 
added verapamil (250/zM) was bound to the 100% DOPG 
LUVET, 50% to the 25% DOPG LUVET, and 33% to the 
100% DOPC LUVET. Compared to doxorubicin, binding 
of verapamil to LUVET composed of 100% DOPC was 
higher. At 50 /zM free drug (and in the presence of 1 mM 
phospholipid) the amount of drug bound per mol DOPC 
was 0.006 and 0.034 mol for doxorubicin and verapamil, 
respectively (Fig. 2B). At DOPG concentrations below 55 
to 60% the amount of verapamil bound to the membranes 
remained higher than doxorubicin. Above this concentra- 
tion the situation was reversed and binding of doxorubicin 
was higher. The relationship between binding of verapamil 
and the concentration of incorporated DOPG was linear, 
whereas a cooperative binding behavior of doxorubicin 
was observed (Fig. 2B). It was not possible to determine 
binding of verapamil at saturation levels, due to the low 
solubility of verapamil n buffer. At pH 7.4 the solubility 
of verapamil s about 800 /zM [38]. 
Next, we compared binding of verapamil to model and 
E. coli cytoplasmic membranes. The different membranes 
employed all contained approximately 25% negatively 
charged phospholipids. Since phosphatidylethanolamine is 
the predominant zwitterionic phospholipid in E. coli, LU- 
VET composed of DOPE/DOPG (3:1) were included next 
to LUVET composed of native E. coli phospholipids. The 
phospholipid composition (on Pi basis) of these LUVET 
was 76% PE, 16% PG, and 6% of the negatively charged 
cardiolipin (CL). The inner membrane vesicles of E. coli 
contained 73% PE, 11% PG, and 14% CL, respectively. A 
decreased binding of verapamil to LUVET composed of 
native E. coli phospholipids and to inner membrane vesi- 
cles (with the latter displaying the lowest binding level) 
than to LUVET composed of DOPC/DOPG lipids was 
observed (Fig. 2C). This difference was not due to the 
presence of PE instead of PC, since binding of verapamil 
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to DOPE/DOPG vesicles was only slightly lower than to 
DOPC/DOPG LUVET (Fig. 2C). No differences were 
observed in verapamil binding when inside-out inner mem- 
brane vesicles or right-side out inner membrane vesicles of 
E. coli were used (data not shown). Note that, as opposed 
to verapamil, doxorubicin binding is higher in the E. coli 
derived membrane systems than in the model 
DOPC/DOPG systems [7]. 
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3.2. Competition between doxorubicin and uerapamil .for 
binding to model and biological membranes 
1.6 
In the presence of 100 /~M doxorubicin a decreased 
binding of verapamil was observed as compared to ab- 
sence of doxorubicin (data not shown). This effect was 
observed in LUVET composed of DOPC containing vari- 
ous amounts of DOPG, LUVET composed of (3:1) 
DOPE/DOPG, or E, coli lipids, and in inner membrane 
vesicles of E. coli. Due to the interference of doxorubicin 
in the verapamil concentration determinations, no accurate 
quantitative data can be given. However, the decrease of 
verapamil bound to the membrane upon addition of 100 
/xM doxorubicin seemed to be largest when inner mem- 
brane vesicles were used and smallest in DOPC/DOPG 
LUVET, in accordance with the difference in binding 
affinities of verapamil and doxorubicin. 
The reverse ffect was also observed. Binding of dox- 
orubicin (total concentration 100 /xM) to membranes de- 
creased in the presence of verapamil (Fig. 3A). The rela- 
tive decrease of doxorubicin binding upon addition of 
verapamil s highest in LUVET composed of 25% DOPG 
and 75% DOPC. In LUVET composed of 100% DOPG the 
number of binding sites for doxorubicin present is so high, 
that the relative decrease of doxorubicin binding upon 
addition of verapamil s low. At low concentrations of PG 
(0 to 5 tool%) the binding of doxorubicin is intrinsically 
low and a significant decrease of binding is hard to 
observe (data not shown). Fig. 3B shows that verapamil 
efficiently competes with doxorubicin binding over a large 
concentration range. This concentration-dependent de- 
crease of bound doxorubicin was also observed in other 
model and biological membranes and a summary of the 
results is shown in Fig. 3C. The largest effect was ob- 
served in DOPC/DOPG (3:1) LUVET, and the smallest in 
inner membrane vesicles of E. coli. This is in accordance 
with the binding behavior of verapamil and doxorubicin 
(see above). The concentration of verapamil at which the 
amount of bound doxorubicin (at 50 /zM free doxorubicin 
and at 1 mM lipid-P~) was 50% compared to that in the 
absence of verapamil appeared to be 130, 182, 189, and 
206 /xM for LUVET composed of DOPC/DOPG, 
DOPE/DOPC, E. coli lipids, and E. coli inner membrane 
vesicles, respectively. 
Also under physiologically more relevant low doxoru- 
bicin concentrations, competition between verapamil and 
doxorubicin occurred. In the presence of 106 /zM lipid-P i 
8% of the added doxorubicin (1 /zM) was bound to DOPC 
vesicles, whereas 42% was bound to DOPG/DOPC LU- 
VET. Also in LUVET containing the negatively charged 
phospholipid DOPS more doxorubicin was bound. PS and 
PE are phospholipids present in the inner leaflet of a 
mammalian plasma membrane and are included here be- 
cause doxorubicin transport experiments were also per- 
formed with these preparations ( ee below). At increasing 
verapamil concentration the amount of free doxorubicin in 
1.4 
o 1.Z 
1.0 
0.8 
142 G. Speelmans et a l . /  Biochimica et Biophysica Acta 1238 (1995) 137-146 
0 ZSO 500 750 1000 1250 
Lipid concentration (/JM Pi) 
Fig. 4. Effect of verapamil on the fluorescence characteristics of doxoru- 
bicin in the absence or presence of membranes. Titration of 10 /xM 
doxorubicin with an increasing amount of lipid-P i of DOPG SUV (O ,Q)  
or DOPC SUV (t3,11), in the presence (closed symbols) or absence 
(open symbols) of 30 /.LM verapamil. 
the presence of DOPC LUVET remained the same, whereas 
the amount of free doxorubicin increased in the presence 
of LUVET containing negatively charged phospholipids 
(Fig. 3D). 
3.3. Effect of uerapamil on the fluorescence behavior of 
doxorubicin in the presence of phospholipids 
The fluorescence behavior of doxorubicin can give 
information about he localization of the drug in the mem- 
brane [6] and so the effects of verapamil on this behavior 
should provide us with information about the location of 
binding competition. At high ratios of doxorubicin/nega- 
tively charged phospholipid self-association f doxorubicin 
occurs at the surface of small unilamellar vesicles (SUV) 
resulting in self quenching due to stacking of the fluores- 
cent aglycon moiety (Fig. 4). Upon dilution of bound 
doxorubicin by titrating more lipid into the cuvette this self 
quenching is relieved and fluorescence becomes even 
higher than in the absence of SUV, due to the fact that the 
aglycon moiety is now residing in the apolar environment 
of the membrane [6,29]. This phenomenon is specific for 
SUV containing anionic phospholipids and is not observed 
for DOPC. The lower affinity of doxorubicin for DOPC 
results only in a gradual an less pronounced increase of 
fluorescence. Verapamil caused a pronounced shift in the 
titration curve (Fig. 4) for DOPG and a smaller shift in that 
for DOPC, At low drug/phospholipid ratios the increase 
of fluorescence was less in the presence of verapamil. At 
high drug/negatively charged phospholipid ratios, the 
maximal self quenching of 10 p~M doxorubicin ow oc- 
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curred at a DOPG concentration of 110 /~M Pi instead of 
56 ~M. The emission spectrum and quantum yield of free 
doxorubicin was not influenced by verapamil (data not 
shown). It can be concluded from these experiments hat 
verapamil competes with doxorubicin for (deep) hydropho- 
bic binding sites and, since it is assumed that self quench- 
ing is due to drug stacking at the membrane surface [6,40], 
the present results also indicate that there is competition i
the presence of anionic phospholipids for binding sites at 
the surface. In the presence of verapamil an increased lipid 
concentration is needed to induce the maximal stacking of 
doxorubicin. 
Competition between verapamil and doxorubicin for 
hydrophobic binding sites is also observed at lower total 
doxorubicin concentrations. Upon addition of 200 /zM 
SUV composed of DOPG to 1 /zM free doxorubicin (high 
lipid/drug ratio) an increase of doxorubicin fluorescence 
was observed. However, this DOPG dependent increase of 
doxorubicin fluorescence was absent when 30 ~M vera- 
pamil was present before DOPG was added, indicating that 
verapamil prevented the insertion of the apolar part of 
doxorubicin into the membrane (data not shown). When 
verapamil was added to doxorubicin after the addition of 
DOPG, i.e., when the doxorubicin was already inserted 
into and/or bound to DOPG SUV, a decrease of doxoru- 
bicin fluorescence up to the fluorescence l vel of free 
doxorubicin was observed, indicating that doxorubicin was 
removed from the (hydrophobic part of the) membrane, 
and/or shifted to the surface of the SUV (data not shown). 
3.4. Increase of the rate of passiue transport of doxoru- 
bicin by L, erapamil across model membranes containing 
anionic phospholipids 
The rate of passive diffusion of doxorubicin across 
membranes containing anionic phospholipids i lower than 
the rate across membranes containing zwitterionic 
phospholipids [37]. This is due to (i) a decreased concert- 
Fig. 5. Passive diffusion of doxorubicin across membranes of DNA 
containing LUVET. (A) Time-based fluorescence trace of doxorubicin 
upon addition of 200 p,M DOPG/DOPC (1:1) LUVET-P, containing 
DNA in the absence (trace a) or presence of 5 /.tM (trace b), 13 ~M 
(trace c), and 20 /.LM verapamil (trace d). Experiments were performed as 
described under Materials and methods at 25°C. 1 /~M doxorubicin was 
added to buffer containing verapamil or (as a control) 0.2% ethanol 
(timepoint 1), giving rise to an immediate increase in fluorescence. After 
the fluorescence signal was stable LUVET were added (timepoint 2). 
Finally, 0.05% Triton X-100 was added to permeabilize the LUVET 
(arrow). (B,C) Permeability coefficient of doxorubicin ( ~m s -  i ) across 
DOPC (m), DOPG/DOPC (1:1) (0) ,  DOPS/DOPC (1:1) (u]), or 
DOPE/DOPS (l : l)  LUVET (O), in the presence of an increasing 
amount of verapamil. The data represent an average of 4 to 12 experi- 
ments, and are not corrected for drug binding (B) or corrected for drug 
binding (C) by dividing the values of the permeability coefficients in (B) 
by the fraction of free doxorubicin. The fraction of free doxorubicin at 
increasing concentrations of verapamil and in the presence of 106 /.tM 
outer leaflet lipid can be deduced from Fig. 3D and can be determined 
accurately (S.D. < 3%). 
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tration of free doxorubicin in the presence of negatively 
charged phospholipids, and (ii) the intrinsic inhibitory 
effect of doxorubicin bound to the membrane on its pas- 
sive diffusion [37]. Therefore, we were interested in the 
effect of verapamil on passive diffusion of doxorubicin. 
The decrease of fluorescence of doxorubicin upon addition 
of LUVET with enclosed DNA is a measure for passive 
diffusion of doxorubicin across the membrane. When LU- 
VET containing 50% of DOPC and 50% of the negatively 
charged DOPG were used, an increase on the rate of 
transport was observed in the presence of an increasing 
concentration of verapamil (Fig. 5A). After calculation of 
the permeability coefficient for doxorubicin across the 
membranes without taking into account the change of 
fraction of transportable (free uncharged) doxorubicin, the 
rate of doxorubicin diffusion is much lower across mem- 
branes containing negatively charged phospholipids (DOPG 
or DOPS) than across membranes composed of the zwitte- 
rionic DOPC (Fig. 5B, [37]). Upon addition of an increas- 
ing amount of verapamil the transport rate was increased 
across membranes containing negatively charged phospho- 
lipids, but not influenced in membranes composed of 
zwitterionic lipids (Fig. 5B). After correction for differ- 
ences in fraction of free drug at each different verapamil 
concentration a higher permeability coefficient in LUVET 
composed of anionic phospholipids was calculated, but the 
permeability coefficient was still lower in anionic 
phospholipid containing LUVET than in 100% DOPC 
LUVET (Fig. 5C, [37]). At increasing verapamil concentra- 
tions permeability coefficients for DOPG or DOPS con- 
taining LUVET now increased to values observed for 
DOPC containing LUVET (Fig. 5C). The enhancing effect 
of verapamil on passive doxorubicin transport was also 
observed for LUVET composed of DOPE/DOPS, as a 
model of the inner leaflet of the plasma membrane of 
mammalian cells. 
Besides the changes in free doxorubicin, the presence of 
verapamil also had effects on the quantum yield of doxoru- 
bicin outside the LUVET and in the lumen of the DNA 
containing LUVET. (This is also reflected in the traces of 
Fig. 5A.) The external quantum yield was decreased 
slightly in the presence of verapamil, due to the fact that 
less doxorubicin was inserted in the hydrophobic part of 
the membrane (see also section 3.3). The internal quantum 
yield was decreased slightly, because a relatively larger 
amount of doxorubicin was now bound to the DNA instead 
of to the membrane. However, the effects of these changes 
in internal and external quantum yield were taken into 
account in the calculation of the permeability coefficient 
[37] for Fig. 5B and C and were low compared to the 
changes in the fraction of free doxorubicin. 
4. Discussion 
This paper describes the effects of the multidrug rever- 
sal agent verapamil on the binding of the anti-cancer drug 
doxorubicin to membranes and on the rate of passive 
diffusion of doxorubicin. We first studied the binding 
behavior of verapamil to model- and biological mem- 
branes and compared it with the binding behavior of 
doxorubicin. Both compounds are amphipathic and posi- 
tively charged at physiological pH. The pK a of verapamil 
is 8.45 [41], comparable with the pK, of doxorubicin 
(8.3), so for both drugs the positively charged species is 
the predominant one at physiological pH. Both drugs 
showed an enhanced binding in the presence of an in- 
creased concentration f negatively charged phospholipids, 
indicating that electrostatic interactions are involved in 
membrane binding for the two drugs. For verapamil the 
relationship between membrane binding and concentration 
of negatively charged phospholipids appears to be linear, 
whereas for doxorubicin a cooperative binding behavior is 
observed [7] probably due to the ability to form stacks at 
the membrane surface [7,40]. Apparently verapamil does 
not form these stacks. Below 55-60% negatively charged 
phospholipids, verapamil bound more strongly to the mem- 
branes than doxorubicin, apparently because hydrophobic 
forces are relatively more important for membrane-binding 
of verapamil as compared to doxorubicin. This is reflected 
in the octanol/water partition coefficients, P, which are 
5.5.102 [41] and 2.5. 10-l [14], for verapamil and dox- 
orubicin, respectively. When various membranes, contain- 
ing approximately the same amount of negatively charged 
phospholipids, were used to study drug binding a differ- 
ence between verapamil and doxorubicin was observed. 
An increase in binding of verapamil is observed in the 
sequence: E. coli inner membrane vesicles, LUVET com- 
posed of E. coli lipid, DOPE/DOPG, and DOPC/DOPG. 
At 50 /zM free verapamil (and 1 mM phospholipid pre- 
sent) the amount of verapamil bound per mol phospholipid 
was 0.011, 0.020, 0.051, and 0.079, respectively. Doxoru- 
bicin exhibits the opposite behavior, namely an increase in 
binding in the sequence: LUVET composed of 
DOPC/DOPG, E. coli lipids, and E. coli inner membrane 
vesicles [7]. At 50 ~M free doxorubicin (and I mM 
phospholipid present) the amount bound per mol phospho- 
lipid is 0.032, 0.22, and 0.93, respectively [7]. This differ- 
ence could be due to a different sensitivity of verapamil 
binding to the presence of membrane proteins (in case of 
inner membrane vesicles) and/or to membrane order, 
which increases with the sequence DOPC/PG, DOPE/PG, 
lipids extracted from E. coli [35]. The latter proposal is in 
accordance with other studies in which an inhibiting effect 
of the presence of cholesterol was observed on Ca ?÷ 
channel antagonists binding to membranes [42]. In contrast 
to verapamil, doxorubicin binding is less sensitive to mem- 
brane order. A higher membrane order promotes tacking 
of doxorubicin at the membrane surface by decreasing the 
penetration of the drug [43]. Thus, high affinity binding 
sites could be formed at the surface instead of in the 
hydrophobic part of the membrane. In accordance, the 
binding of doxorubicin to the various membrane types is 
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equal at low doxorubicin concentrations (below 10 /zM), 
even in membranes with a higher order. 
In the presence of doxorubicin less verapamil was 
bound to membranes and visa versa. Competition between 
daunorubicin and verapamil for binding to model mem- 
branes has been observed elsewhere [30,44], but the effects 
were smaller, probably because no negatively charged 
phospholipids were used in those cases. The concentration 
of verapamil at which the amount of bound doxorubicin (at 
50 /zM free doxorubicin and at 1 mM lipid@ i) was 50% 
compared to that in the absence of verapamil appeared to 
be 130, 182, 189, and 206 /zM for LUVET composed of 
DOPC/DOPG, DOPE/DOPC, E. coli lipids, and E. coli 
inner membrane vesicles, respectively. The apparent affin- 
ity of doxorubicin for DOPC/DOPG (3:1) LUVET and 
LUVET composed of E. coli phospholipids, expressed as 
the concentration f free doxorubicin at which 50% of the 
maximal doxorubicin binding occurs (in the presence of 1 
mM lipid-Pi), is 360 and 256 /.LM [6,7], which is in the 
same order of magnitude. Verapamil is thought to be 
located in the hydrophobic part of the membrane near the 
headgroup region [42] so it was expected to compete with 
doxorubicin for the hydrophobic binding sites and this 
seems to be the case. However, in the presence of anionic 
phospholipids verapamil had a stronger effect on binding 
of doxorubicin to both 'deep' and 'surfacial' binding sites, 
in both cases probably by neutralization f negative charges 
of the phospholipids. 
Interestingly, verapamil showed an enhancing effect on 
the rate of passive diffusion of doxorubicin. This effect 
was specifically observed with LUVET composed of nega- 
tively charged phospholipids. Our explanation for this 
phenomenon is the following: binding of doxorubicin to 
the membrane decreases the rate of its passive diffusion 
[37], and since in the presence of verapamil doxorubicin 
binding is diminished, an increased iffusion rate of dox- 
orubicin is the result. In previous work we showed that the 
rate of passive influx of doxorubicin across model mem- 
branes in which DNA was enclosed is decreased when 
anionic phospholipids are present. This effect is due to (i) 
a decrease of the amount of free, transportable drug, and 
(ii) an intrinsic effect, since even after correction for 
doxorubicin binding, a significantly lower influx rate was 
observed in the presence of anionic phospholipids [37]. 
Probably, the incorporation of doxornbicin close to the 
surface of the membrane induces a tightening of the 
interfacial region and hinders passive diffusion of doxoru- 
bicin, which is relieved upon the displacement with vera- 
pamil. So verapamil enhances passive diffusion of doxoru- 
bicin by (i) increasing the concentration of transportable 
doxorubicin and by (ii) diminishing the intrinsic mem- 
brane-disturbing, inhibitory effect of positively charged, 
membrane-bound doxorubicin. Although an increase in 
membrane fluidity has been described upon incorporation 
of a high amount of verapamil, which can also enhance 
passive diffusion, this effect was not observed under the 
conditions of our transport experiments [40]. Furthermore, 
we tested the effect of verapamil on carboxyfluorescein 
(CF) efflux from LUVET containing DOPG and observed 
no CF leakage under transport experiment conditions (data 
not shown), indicating that under transport experiment 
conditions the membrane barrier function was not dis- 
rupted by verapamil. 
Our findings might have implications for drug transport 
studies in intact cancer cells. In previous studies the pas- 
sive flow of anthracyclines was determined by blocking 
the active efflux pump, P-glycoprotein, by adding vera- 
pamil [45]. However, our studies on model systems indi- 
cate that passive transport and permeability coefficients are 
not the same in the presence and absence of verapamil and 
competition for binding between verapamil and doxoru- 
bicin will initially increase the amount of cytosolic non- 
membrane-bound drug in sensitive and multidrug resistant 
cancer cells. In addition, the enhancing effect of verapamil 
on passive influx of doxorubicin will have a sensitizing 
effect in multidrug resistant cancer cells by reducing the 
effect of the pump because of increased leak. Studies in 
cancer cells often show an effect of verapamil on the 
sensitive, parental strain or on multidrug resistance cells 
that do not contain P-glycoprotein (although the effects are 
usually smaller than in P-glycoprotein containing cells). 
These effects were thought o result from a residual or 
undetectable amount of P-glycoprotein or the presence of 
another active pump [22,28,45-49]. Direct effects of vera- 
pamil on phospholipids offer (at least partially) an alterna- 
tive explanation for these phenomena, since at least in 
model membranes the ratio DNA-bound doxorubicin ver- 
sus free plus membrane-bound doxorubicin is increased 
(see Fig. 5A). If this phenomenon can also be observed in 
more complex systems such as cancer cells we do not 
know. Taking into account the physico-chemical properties 
of mdr substrates and mdr reversal agents [14] we assume 
that the effects of verapamil on internal doxornbicin con- 
centration is not specific and that these effects will be 
general for mdr reversal agents. 
It can be concluded that verapamil can sensitize mdr 
cells to anti-cancer drugs such as doxorubicin by more 
than one mechanism, namely (i) by a direct effect of 
verapamil on the P-glycoprotein (i.e., occupying a different 
binding site on the protein or competing for the same 
binding site both resulting in a lower active efflux) [16-20], 
and (ii) by a competition between doxorubicin and vera- 
pamil for binding on the phospholipid part of the mem- 
brane including its subsequent enhancing effects on pas- 
sive doxorubicin transport. Finally, an indirect effect of 
verapamil on the active efflux of doxorubicin by the 
P-glycoprotein or another mdr-conferring active pump can 
be speculated upon. If a direct pumping of the drug from 
the interphase of the inner leaflet is assumed [12,50], 
because the positively charged, moderately hydrophobic 
anti-cancer drugs accumulate at that position, our results 
indicate that verapamil lowers the substrate concentration 
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in the compartment from which the enzyme pumps, which 
might have kinetic effects on the pump activity. 
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